Group 1 - The company Shandong Weigao Blood Purification Products Co., Ltd. has received approval for its initial public offering (IPO) of A-shares and will be listed on the main board [1][2] - The total number of shares to be issued is 41,139,407 shares, with an initial strategic placement of 4,113,940 shares, accounting for 10% of the total issuance [2] - The final strategic placement amount is 1,772,075 shares, approximately 4.31% of the total issuance, leading to a total of 28,259,832 shares available for offline and online distribution [2][3] Group 2 - The IPO price is set at 26.50 yuan per share, with the initial issuance of 11,107,500 shares scheduled for May 8, 2025 [2][3] - The online subscription received an oversubscription rate of approximately 7,518.35 times, prompting the activation of a mechanism to adjust the allocation between offline and online investors [2][3] - After the adjustment, the final allocation is 12,512,832 shares for offline investors (31.78%) and 26,854,500 shares for online investors (68.22%) [3] Group 3 - The final online winning rate for investors is approximately 0.03215719% [3] - Investors are required to fulfill their payment obligations by May 12, 2025, and must ensure sufficient funds in their accounts [4] - The company has established a lock-up period of 6 months for 10% of the shares allocated to strategic placement investors, while 90% of the shares will be tradable immediately after listing [5][6] Group 4 - The strategic placement includes a special asset management plan for the company's senior management and core employees, managed by Huatai Securities [6][7] - The total amount of funds committed by strategic placement investors has been received in full by the underwriter [7] - The online lottery for share allocation was conducted on May 9, 2025, with a total of 53,709 winning numbers announced [8][9]
威高血净: 威高血净首次公开发行股票并在主板上市网下初步配售结果及网上中签结果公告
Zheng Quan Zhi Xing·2025-05-11 09:25